We performed a needs assessment by conducting 193 interviews and surveys with clinicians, patients, tobacco treatment specialists, nurses, and administrators, in order to determine the barriers to tobacco control delivery. New tobacco control program services were implemented [7 (link)].
After the identification of a patient with current tobacco use, physicians were prompted to refer the patient to tobacco cessation. A multilingual tobacco treatment specialist (TTS) conducted a culturally sensitive motivational interview, gave educational materials, and referred the consenting patient for a tobacco cessation consultation. Patients with a qualifying tobacco use history were referred by the physicians themselves or with TTS prompting to LDCT screening. The use of multilingual support overcame a significant barrier to LCS in patients from racial and ethnic minority groups. Physicians considered patient life expectancy and willingness to have screening and potentially curative therapy before referral to LDCT screening.
We reviewed the tobacco use assessments and engagement with the tobacco control program by race and ethnicity across the City of Hope southern California treatment sites in 2021 (1 academic center and 40 community centers). We analyzed LCS rates and tobacco cessation referral rates, and cessation effectiveness after program implementation.
The COH tobacco control program consisted of quality improvement projects. This was submitted to the COH investigational review board, which concluded the program was deemed non-human-subject research. Therefore, no patient informed consent was required (IRB number 19201).
These new services were implemented in 2019 and continued until the present. Observational evaluations began in 2019 pre- and post-implementation.
After the identification of a patient with current tobacco use, physicians were prompted to refer the patient to tobacco cessation. A multilingual tobacco treatment specialist (TTS) conducted a culturally sensitive motivational interview, gave educational materials, and referred the consenting patient for a tobacco cessation consultation. Patients with a qualifying tobacco use history were referred by the physicians themselves or with TTS prompting to LDCT screening. The use of multilingual support overcame a significant barrier to LCS in patients from racial and ethnic minority groups. Physicians considered patient life expectancy and willingness to have screening and potentially curative therapy before referral to LDCT screening.
We reviewed the tobacco use assessments and engagement with the tobacco control program by race and ethnicity across the City of Hope southern California treatment sites in 2021 (1 academic center and 40 community centers). We analyzed LCS rates and tobacco cessation referral rates, and cessation effectiveness after program implementation.
The COH tobacco control program consisted of quality improvement projects. This was submitted to the COH investigational review board, which concluded the program was deemed non-human-subject research. Therefore, no patient informed consent was required (IRB number 19201).
These new services were implemented in 2019 and continued until the present. Observational evaluations began in 2019 pre- and post-implementation.
Free full text: Click here
